AstraZeneca forms an AI deal in China ; Third Harmonic advances liquidation plans

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock ...